Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Down 73.1% in August

Key Points

• Pharming Group N.V. experienced a significant 73.1% decrease in short interest in August, dropping from 5,200 shares to 1,400 shares as of August 15th.
• Institutional investor Silverberg Bernstein Capital Management LLC raised its position in Pharming Group by 8.6% during the second quarter, now holding 52,147 shares valued at approximately $557,000.
• Pharming Group's stock has shown a 6.1% increase recently, trading at $14.87, with a market capitalization of $1.02 billion and a reported revenue of $93.20 million for the last quarter.

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) was the recipient of a large decrease in short interest during the month of August. As of August 15th, there was short interest totaling 1,400 shares, adecreaseof73.1% from the July 31st total of 5,200 shares. Based on an average trading volume of 7,000 shares, the short-interest ratio is currently 0.2 days. Based on an average trading volume of 7,000 shares, the short-interest ratio is currently 0.2 days.

Institutional Trading of Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its position in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) by 8.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 52,147 shares of the company's stock after purchasing an additional 4,150 shares during the quarter. Silverberg Bernstein Capital Management LLC owned 0.08% of Pharming Group worth $557,000 as of its most recent filing with the Securities and Exchange Commission. 0.03% of the stock is currently owned by institutional investors.

Pharming Group Trading Up 6.1%

Shares of Pharming Group stock traded up $0.86 during mid-day trading on Wednesday, hitting $14.87. 5,593 shares of the stock were exchanged, compared to its average volume of 6,409. Pharming Group has a twelve month low of $6.73 and a twelve month high of $17.08. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of -112.35 and a beta of 0.05. The company has a 50-day simple moving average of $11.45 and a 200 day simple moving average of $10.07. The company has a current ratio of 2.79, a quick ratio of 2.07 and a debt-to-equity ratio of 0.38.

Pharming Group (NASDAQ:PHAR - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.16. Pharming Group had a negative net margin of 2.19% and a negative return on equity of 3.31%. The company had revenue of $93.20 million for the quarter, compared to analysts' expectations of $70.36 million. Pharming Group has set its FY 2025 guidance at EPS. Research analysts forecast that Pharming Group will post -0.2 EPS for the current year.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.